Radiopharm Theranostics (ASX:RAD) Accounts Payable: A$6.35 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Radiopharm Theranostics Accounts Payable?

Radiopharm Theranostics ASX:RAD Accounts Payable is A$6.35 Mil as of Jun. 2025. The stock has 5 warning signs investors should review.

Radiopharm Theranostics's Accounts Payable for the quarter that ended in Jun. 2025 was A$6.35 Mil.

Radiopharm Theranostics's quarterly Accounts Payable declined from Jun. 2024 (A$6.44 Mil) to Dec. 2024 (A$3.14 Mil) but then increased from Dec. 2024 (A$3.14 Mil) to Jun. 2025 (A$6.35 Mil).

Radiopharm Theranostics's annual Accounts Payable increased from Jun. 2023 (A$2.96 Mil) to Jun. 2024 (A$6.44 Mil) but then declined from Jun. 2024 (A$6.44 Mil) to Jun. 2025 (A$6.35 Mil).

Radiopharm Theranostics Accounts Payable Related Terms

Radiopharm Theranostics Accounts Payable Historical Data

* Premium members only.

The historical data trend for Radiopharm Theranostics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radiopharm Theranostics Accounts Payable Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Accounts Payable
1.19 2.96 6.44 6.35

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Accounts Payable Get a 7-Day Free Trial 2.96 9.02 6.44 3.14 6.35

Radiopharm Theranostics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of A$6.35 Mil mean?
Radiopharm Theranostics (ASX:RAD) has a Accounts Payable of A$6.35 Mil as of Jun. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Radiopharm Theranostics and its competitors.
Is Radiopharm Theranostics' Accounts Payable too high?
Radiopharm Theranostics' current Accounts Payable is A$6.35 Mil.
How does Radiopharm Theranostics' Accounts Payable compare to VRTX and REGN?
Radiopharm Theranostics' Accounts Payable of A$6.35 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Radiopharm Theranostics and its competitors. Radiopharm Theranostics's current Accounts Payable is A$6.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Radiopharm Theranostics (ASX:RAD) has a current Accounts Payable of A$6.35 Mil. The current Accounts Payable is A$6.35 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Radiopharm Theranostics (ASX:RAD), the current Accounts Payable is A$6.35 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Radiopharm Theranostics Business Description

Other Exchanges RADX:USA
Address 62 Lygon Street, Suite 1, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.